

PEDIATRIC TB RISK ASSESSMENT FORM

Physician/ Health Provider:	none:	Date:	
Child's Name:			
Address: Ci			
Sex: ☐ Male ☐ Female Hispanic: ☐ No ☐ Yes Race: ☐ White ☐ Black ☐ Asian ☐ Am. Indian/Nat. Alaskan ☐ Other			
US Born: ☐Yes ☐No If no, US Date of Arrival:/ Country of Birth:			
Parent/Guardian:		Phone:	
TB RISK FACTORS:			
1. Does the child have any symptoms of TB (cough, fever night sweats, loss of appetite, weight loss or fatigue) or a abnormal chest X-ray?		If yes, name of symptoms:	
2. In the last 2 years, has the child lived with or spent time with someone who has been sick with TB?	ne □Yes □No		
3. Was the child born in Africa, Asia, Pacific Islands (excel Japan), Central America, South America, Mexico, Eastern Europe, The Caribbean or the Middle East?	•	If yes, in what country was the child born:	
4. Has the child lived or traveled in Africa, Asia, Pacific Isl (except Japan), Central America, South America, Mexico, Eastern Europe, The Caribbean or the Middle East for mothan one month?	□Ves □No	If yes, in what country did the child travel to:	
5. Have any members of the child's household come to the United States from another country?	he	If yes, name of country:	
 6. Is the child exposed to a person who: Is currently in jail or who has been in jail in the payears? Has HIV? Is homeless? Lives in a group home? Uses illegal drugs? Is a migrant farm worker? 	ast 5 ☐Yes ☐No	If yes, name the risk factors the child is exposed to:	
7. Is the child/teen in jail or ever been in jail?	□Yes □No	If yes, name of jail:	
8. Does the child have any history of immunosuppressive disease or take medications that might cause immunosuppression?	e □Yes □No	If yes, name of disease or medications:	

If yes, to any of the above, the child has an increased risk of TB infection and should have a TST/IGRA.

All children with a positive TST/IGRA result must have a medical evaluation, including a chest X-ray. Treatment for latent TB infection should be initiated if the chest X-ray is normal and there are no signs of active TB. If testing was done, please attach or enter results on next page.

MEDICAL INFORMATION:		
Primary Reason for Evaluation: ☐ Contact Investigation ☐ Incidental Abnormal C		
☐Other:		
Symptomatic: ☐ No ☐ Yes If Yes, ONSET date:/_		
Symptoms: ☐ Cough ☐ Hemoptysis ☐ Fever ☐ Other:	□ Night Sweats □ Weight Loss ofIbs.	
Tuberculin Skin Test (TST/Mantoux/PPD)	Induration: mm	
Date Given:/	Impression: ☐ Negative ☐ Positive	
Interferon Gamma Release Assay (IGRA) Date:/	Impression: ☐ Negative ☐ Positive ☐ Indeterminate	
Chest X-ray (required with positive TST or IGRA) Date://	Impression: ☐ Normal ☐ Abnormal findings	
☐ LTBI treatment (Rx and start date): Rx: Date:/ ☐ Contraindications to INH or rifampin for LTBI	☐ Prior TB/LTBI treatment (Rx and duration): Rx:mm ☐ Offered but refused LTBI treatment	
ADDITIONAL COMMENTS:		
RECOMMENDATIONS:		
Health Provider Signature:	Date Completed:/	

IIDPH ILLLINOIS DEPARTMENT OF PUBLIC HEALTH

PEDIATRIC TB RISK ASSESSMENT INSTRUCTIONS

Tuberculosis risk assessment should be performed at first contact with a child and every 6 months thereafter for the first 2 years of life. After 2 years of age, risk assessment for tuberculosis should be performed annually. A Mantoux tuberculin skin test (TST) should be performed by a trained healthcare provider and read 48-72 hours later by a trained healthcare provider. Any positive TST in a child <5 years of age is reportable to the local county health department. Any child with a latent TB infection (LTBI) should be treated with Isoniazid for 9 months in conjunction with the local county health department. Children <15 years of age need directly observed preventive therapy (DOT).

RISK FACTORS FOR TUBERCULOSIS (TB) IN CHILDREN

- Have clinical evidence or symptoms of TB
- Have a family member or contacts with history of confirmed or suspected TB
- Are in foreign-born families from TB endemic countries
- Travel to countries with high rate of TB
- Contact with individual(s) with a positive TB test
- Abnormalities on chest X-ray suggestive of TB
- Adopted from any high-risk area or live in out-ofhome placements

- Live with an adult who has been incarcerated in the last five years
- Live among or frequently exposed to individuals who are homeless, migrant farm workers, residents of nursing homes, or users of street drugs
- Drink raw milk or eat unpasteurized cheese (e.g., queso fresco or unpasteurized cheese)
- Have or are suspected to have, HIV infection or live with an adult with HIV seropositivity.

TESTING METHODS

A Mantoux tuberculin skin test (TST) or an Interferon Gamma Release Assay (IGRA) (for children aged 4 and older) should be used to test those at increased risk. A TST ≥10mm is considered positive. If a child has had contact with someone with active TB then TST ≥5mm is considered positive. If a TB skin test result is negative for a child less than six (6) months, please retest the child at six (6) months of age.

Screening should be performed by CXR in addition to TST/IGRA and symptom review in HIV infected or suspected HIV, other immunocompromised conditions or if a child is taking immunosuppressive medications such as prednisone or TNF-alpha antagonists.

A "yes" answer to question #1 or #2 indicates the child should have an immediate TST regardless of age.

A "yes" answer to question #3, #4, #5, or #6 indicates the child should have an initial TST. Additional TSTs should only be done when a new risk factor/exposure occurs.

A "yes" answer to question #7 or #8 indicates the child should have an initial TST, regardless of age, and then an annual TST.

REFERRAL, TREATMENT, AND FOLLOW-UP OF CHILDREN WITH POSITIVE TB TESTS

- All children with a positive TST or IGRA result should have a medical evaluation, including a chest X-ray.
- Report any confirmed or suspected case of TB disease to the TB Control Program within 7 days, including any child with an abnormal chest X-ray.
- If TB disease is not found, treat children and adolescents with a positive TST or IGRA for latent TB infection (LTBI)
- Isoniazid (INH) is the drug of choice for the treatment of LTBI in children in adolescents. The length of treatment is 9 months with daily dosing: 10-15mg/kg (maximum 300mg).
- For management and treatment guidelines for TB or LTBI, go to: www.cdc.gov/tb or contact the TB Control Program at (217) 785-5371